Teva pharmaceutical industries ltd (TEVA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Net revenues

16,887

18,271

21,853

21,903

19,652

20,272

20,314

20,317

18,312

16,121

13,899

11,085

9,408

Cost of sales

9,351

9,975

11,237

10,250

8,296

9,216

9,607

9,665

8,797

7,056

6,532

5,117

4,531

Gross profit

7,537

8,296

10,615

11,653

11,356

11,056

10,707

10,652

9,515

9,065

7,367

5,968

4,877

Research and development expenses

1,010

1,213

1,778

2,077

1,525

1,488

1,427

1,356

1,095

951

825

786

581

Selling and marketing expenses

2,614

2,916

3,395

3,583

3,478

3,861

4,080

3,879

3,478

2,968

2,676

1,842

1,264

General and administrative expenses

1,192

1,298

1,451

1,390

1,360

1,217

1,239

1,238

932

865

823

669

637

Intangible assets impairments

1,639

1,991

3,238

589

-

-

-

-

-

-

-

-

-

Goodwill impairment

-

3,027

17,100

900

0

0

-

-

-

-

-

-

-

Other assets impairments, restructuring and other items

423

987

1,836

830

1,176

650

788

1,259

430

-

-

-

-

Legal settlements and loss contingencies

1,178

-1,208

500

899

631

-111

1,524

715

471

410

-638

-124

0

Other income

76

291

1,199

769

166

-

-

-

-

-

-

-

-

Purchase of research and development in process

-

-

-

-

-

-

-

-

-

-

-

1,402

0

Operating (loss) income

-443

-1,637

-17,484

2,154

3,352

3,951

1,649

2,205

3,109

3,871

2,405

1,145

2,395

Financial expenses, net

-822

-959

-895

-1,330

-1,000

-313

-399

-386

-153

-225

-202

-345

-91

Income (loss) before income taxes

-1,265

-2,596

-18,379

824

2,352

3,638

1,250

1,819

2,956

3,646

2,203

800

2,304

Income taxes (benefit)

-278

-195

-1,933

521

634

591

-43

-137

127

283

166

184

386

Income before minority interest earnings and equity investments

-

-

-

-

-

-

-

-

-

-

-

-616

1,918

Share in (profits) losses of associated companies, net

-13

-71

-3

8

-121

-5

-40

-46

-61

-24

-33

-1

-3

Net income (loss)

-1,000

-2,472

-16,449

311

1,597

3,042

1,253

1,910

2,768

3,339

2,004

615

1,915

Net income (loss) attributable to non-controlling interests

-2

-322

-184

-18

9

-13

-16

-53

9

8

4

6

1

Net income (loss) attributable to Teva

-999

-2,150

-16,265

329

1,588

3,055

1,269

1,963

2,759

3,331

2,000

609

1,914

Accrued dividends on preferred shares

-

249

260

261

15

0

-

-

-

-

-

-

-

Net income (loss) attributable to ordinary shareholders

-999

-2,399

-16,525

68

1,573

3,055

1,269

-

-

-

-

-

-

Earnings (loss) per share attributable to ordinary shareholders:
Basic

-0.91

-2.35

-16.26

0.07

1.84

3.58

1.49

2.25

3.10

3.72

2.29

0.78

2.49

Diluted

-0.91

-2.35

-16.26

0.07

1.82

3.56

1.49

2.25

3.09

3.67

2.23

0.75

2.36

Weighted average number of shares (in millions):
Basic

1,091

1,021

1,016

0

855

853

849

872

890

896

872

780

768

Diluted

1,091

1,021

1,016

0

864

858

850

873

893

921

896

820

830